ReviewWorld journal of surgery2020
Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor.
Review in World journal of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2025Pooled it
- Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology · 2025Pooled it
- A Rare Case of Asymptomatic Insulinoma with Mesocolonic Lymph Node Metastases and Long-Term Stability.Surgical case reports · 2026Article
- History of an Insidious Case of Metastatic Insulinoma.Journal of clinical medicine · 2025Article
- Metastatic insulinoma-outcomes in the current era.The oncologist · 2025Article
- Incidence and risk factors for insulinoma diagnosed in dogs under primary veterinary care in the UK.Scientific reports · 2025Article
- Single-cell transcriptome conservation in a multispecies comparative analysis of fresh and cryopreserved insulinoma cell lines.Veterinary oncology (London, England) · 2025Article
- NON-FUNCTIONING SPORADIC PANCREATIC NEUROENDOCRINE TUMOR IS AN INDEPENDENT RISK FACTOR FOR RECURRENCE AFTER SURGICAL TREATMENT.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Small Insulinoma Followed-up as an Indolent Pancreatic Tumor.Internal medicine (Tokyo, Japan) · 2024Article
- A Rare and Aggressive Case of Malignant Insulinoma.Cureus · 2024Article
- Single center experience in localization of insulinoma by selective intraarterial calcium stimulation angiography - a case series of 15 years.Frontiers in endocrinology · 2024Article
- Transformation of pancreatic nonfunctioning neuroendocrine tumor into metastatic insulinoma: A rare case report.Clinical case reports · 2023Article
- Epidemiological trends for functional pancreatic neuroendocrine tumors: A study combining multiple imputation with age adjustment.Frontiers in endocrinology · 2023Article
- Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics.Frontiers in oncology · 2023Article
- Current Trends in Diagnosis, Treatment and Prognosis of Canine Insulinoma.Veterinary sciences · 2022Review
- Malignant insulinoma in a patient with hypoglycemia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Metastatic insulinoma presenting after bariatric surgery in a patient diagnosed with MEN1.Clinical case reports · 2022Article
- Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE.Frontiers in endocrinology · 2022Review
- Hepatic Artery Embolization for Palliation of Symptomatic Hypoglycemia in Patients With Hepatic Insulinoma Metastases.Journal of the Endocrine Society · 2021Article
- Long-term morbidity and mortality in patients diagnosed with an insulinoma.European journal of endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
introductionDue to the rarity of malignant insulinoma, a lack of the literature describing factors affecting outcomes exists. Our aim was to review malignant insulinoma incidence, characteristics and survival trends.
methodsWe identified all patients with malignant insulinoma in the SEER registries from 1973 to 2015. Incidence, neoplasm characteristics and factors affecting cancer-specific survival (CSS) were described.
resultsA total of 121 patients were identified. The crude annual overall incidence was low (range 0.0-0.27 cases per million person years). The largest proportion had localized disease (40%), while 16% had regional disease, 39% distant metastatic disease, and stage was unreported in 5%. Most neoplasms were in the body/tail of the pancreas, followed by the head of the pancreas. Grade was reported in 40% of patients; only a single patient reported as having grade IV with the remainder all grades I/II. Surgical resection was performed in 64% of patients. Within surgical patients, the median primary neoplasm size was 1.8 cm. Regional lymph nodes were examined in 57.1% of surgical patients, while 34% of examined nodes were positive. The median CSS was 183 months. On multivariable analysis, surgical resection, male sex and absence of metastatic disease were associated with superior survival.
conclusionWhile the greatest proportion of patients with malignant insulinoma present with localized disease, regional lymph node involvement was found in 34% of whose nodes were tested. Further studies are needed to assess the role of lymph node dissection in improving survival and preventing recurrence given the observed frequency of lymph node involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.